Halozyme Therapeutics Executive Compensation Revealed
Ticker: HALO · Form: DEF 14A · Filed: Mar 18, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | DEF 14A |
| Filed Date | Mar 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Halozyme's exec pay details out, showing stock awards and vesting info for 2024.
AI Summary
Halozyme Therapeutics, Inc. filed its DEF 14A on March 18, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards, options, and stock values for its PEO (Principal Executive Officer) and other named executive officers. Specific details on outstanding, unvested, and vested equity awards granted in prior years are provided, along with those that failed to meet vesting conditions.
Why It Matters
This filing provides transparency into how Halozyme Therapeutics compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.
Risk Assessment
Risk Level: low — This is a routine proxy statement detailing executive compensation and is not indicative of immediate financial risk.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Filer of the DEF 14A
- 0001159036-25-000016 (filing_id) — Accession Number for the filing
- 20250318 (date) — Filing Date
- 20241231 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide detailed information regarding the executive compensation of Halozyme Therapeutics, Inc. for the fiscal year ending December 31, 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on March 18, 2025.
What period does the compensation information in this filing cover?
The compensation information in this filing primarily covers the fiscal year ending December 31, 2024.
What specific types of compensation are detailed in the filing?
The filing details equity awards, options, and stock values, including outstanding, unvested, and vested awards, as well as those that failed to meet vesting conditions.
What is the company's Standard Industrial Classification (SIC) code?
The company's Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 18, 2025 regarding HALOZYME THERAPEUTICS, INC. (HALO).